CAS Number100286-90-6
SynonymsCampto hydrochloride; Campto; Camptothecin 11 hydrochloride; Irinotecan hydrochloride; CPT-11 hydrochloride; irinotecan hydrochloride (anhydrous); Irinotecan Hcl; CPT 11; Camptothecin analog; MFCD01862255; Irinotecan (hydrochloride)
Molecular FormulaC33H39ClN4O6
Molecular Weight623.14
Purity≥97 (HPLC)%
Boiling Point257 °C
Melting Point250-256°C (dec.)
Appearancepowder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 100286-90-6 |
| Catalog No. | 2A-9049700 |
| Chinese Name | 盐酸依立替康 |
| Synonyms | Campto hydrochloride; Campto; Camptothecin 11 hydrochloride; Irinotecan hydrochloride; CPT-11 hydrochloride; irinotecan hydrochloride (anhydrous); Irinotecan Hcl; CPT 11; Camptothecin analog; MFCD01862255; Irinotecan (hydrochloride) |
| Molecular Formula | C33H39ClN4O6 |
| Molecular Weight | 623.14 |
| Purity | ≥97 (HPLC) |
| Boiling Point | 257 °C |
| Melting Point | 250-256°C (dec.) |
| Appearance | powder |
| Storage Condition | Store airtight in a cool, dry warehouse. Refrigera |
| Application | Irinotecan hydrochloride is a water-soluble topoisomerase I inhibitor mainly used to treat colon and rectal cancer. |
| PubChem ID | 329815350 |
| MDL Number | MFCD01862255 |
| SMILES | Cl.CCc1c2CN3C(=O)C4=C(C=C3c2nc5ccc(OC(=O)N6CCC(CC6)N7CCCCC7)cc15)[C@@](O)(CC)C(=O)OC4 |
| InChI | 1S/C33H38N4O6.ClH/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2;/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3;1H/t33-;/m0./s1 |
| InChI Key | GURKHSYORGJETM-WAQYZQTGSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352204 |
| Hazard Symbols | transportation |
| MSDS | msds/49700_1_100286_90_6.pdf |
| Bioactivity | Irinotecan hydrochloride is a water soluble topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Cell Cycle/DNA Damage >> Topoisomerase Research Areas >> Cancer Target Topoisomerase I In Vitro Irinotecan hydrochloride is a topoisomerase I inhibitor. Irinotecan inhibits the growth of LoVo and HT-29 cells, with IC50s of 15.8 ± 5.1 and 5.17 ± 1.4 μM, respectively, and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells[2]. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC), with an IC50 of 1.3 μM[3]. In Vivo Irinotecan (CPT-11, 5 mg/kg) significantly inhibits the growth of tumors by intratumoral injection daily for 5 days, on two consecutive weeks in rats, and such effects also occur via continuous intraperitoneal infusion by osmotic minipump into mice. However, Irinotecan (10 mg/kg) shows no effect on the growth of tumor by i.p[1]. Irinotecan (CPT-11, 100-300 mg/kg, i.p.) apparently suppresses tumor growth of HT-29 xenografts in athymic female mice by day 21. The two groups of Irinotecan (125 mg/kg) plus TSP-1 (10 mg/kg per day) or Irinotecan (150 mg/kg) in combination TSP-1 (20 mg/kg per day) are nearly equally effective and inhibit tumor growth 84% and 89%, respectively, and both are more effective than Irinotecan alone at doses of 250 and 300 mg/kg[3]. Cell Assay Exponentially growing cells are seeded in 20 cm2 dishes with an optimal cell number for each cell line (20,000 for LoVo cells, 100,000 for HT-29 cells). They are treated 2 days later with increasing concentrations of irinotecan or SN-38 for one cell doubling time (24 h for LoVo cells, 40 h for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the drug concentrations responsible for 50% growth inhibition as compared with cells incubated without drug[2]. Animal Admin Irinotecan has been administered by intratumoral injection at 0.1 cc volume of the appropriate solution, for a doses of 5 mg/kg daily for 5 days, on two consecutive weeks, followed by a 7-days rest period, referred to as one cycle of therapy. Rats receive three cycles over a period of 8 weeks. Control animals receive 0.1 cc of sterile 0.9% sodium chloride solution by intratumoral injection in the same rule of administration as that of animals of group II[1]. References [1]. Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56(3):219-26. [2]. Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49(4):329-35. Epub 2002 Jan 30. [3]. Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5. Chemical & Physical Properties Boiling Point 257 °C Melting Point 250-256°C (dec.) Molecular Formula C33H39ClN4O6 Molecular Weight 623.139 Flash Point 482ºC Exact Mass 622.255798 PSA 114.20000 LogP 4.76890 Vapour Pressure 1.31E-32mmHg at 25°C Index of Refraction 67.7 ° (C=1, H2O) InChIKey GURKHSYORGJETM-WAQYZQTGSA-N SMILES CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(O)CC.Cl Storage condition Refrigerator |
| Use of | Irinotecan hydrochloride is a water soluble topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer. Properties Articles123 Name Irinotecan hydrochloride Synonym More Synonyms Irinotecan hydrochloride Biological Activity Description Irinotecan hydrochloride is a water soluble topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Cell Cycle/DNA Damage >> Topoisomerase Research Areas >> Cancer Topoisomerase I References [1]. Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56(3):219-26. [2]. Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49(4):329-35. Epub 2002 Jan 30. [3]. Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5. Chemical & Physical Properties Exact Mass 622.255798 PSA 114.20000 LogP 4.76890 InChIKey GURKHSYORGJETM-WAQYZQTGSA-N Storage condition Refrigerator |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 United Nations shipping name European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Finasteride | 98319-26-7 | 2A-9049494 |
| Interferon Alfa-2b | 98530-12-2 | 2A-9049515 |
| Teriparatide acetate hydrate | 99294-94-7 | 2A-9049603 |
| Venlafaxine hydrochloride | 99300-78-4 | 2A-9049607 |
| Domperidone maleate | 99497-03-7 | 2A-9049628 |
| 25-O-Deacetyl Rifabutin | 100324-63-8 | 2A-9049706 |
| Estriol trisulfate trisodium salt | 100940-55-4 | 2A-9049776 |
| Levetiracetam | 102767-28-2 | 2A-9049931 |
| Levamlodipine | 103129-82-4 | 2A-9049970 |
| Levetiracetam acid | 103833-72-3 | 2A-9050043 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS